PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway

被引:37
作者
Cao, Lianjing [1 ,2 ,3 ,4 ]
Wang, Fan [1 ,2 ,3 ]
Li, Shouying [1 ,2 ,3 ]
Wang, Xinyue [1 ,2 ,3 ]
Huang, Dingzhi [1 ,2 ,3 ]
Jiang, Richeng [1 ,2 ,3 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China
[2] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Thorac Oncol, Tianjin Lung Canc Ctr, Tianjin 300060, Peoples R China
[4] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
PIM1; c-MET; eIF4B; Lung adenocarcinoma; PROTOONCOGENE PIM-1; PROTEIN-KINASE; PHASE-II; CANCER; EXPRESSION; INHIBITOR; ACTIVATION; MECHANISMS; SGI-1776; THERAPY;
D O I
10.1016/j.canlet.2018.12.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The proto-oncogene PIM1 plays essential roles in proliferation, survival, metastasis and drug resistance in hematopoietic and solid tumors. Although PIM1 has been shown to be associated with lymph node metastasis and poor prognosis in non-small cell lung cancer, its underlying molecular mechanisms in this context are still unclear. Here we show that PIM1 is frequently overexpressed in lung adenocarcinomas, and its expression level is associated with c-MET expression and poor clinical outcome. We further demonstrate that PIM1 may regulate c-MET expression via phosphorylation of eukaryotic translation initiation factor 4B (eIF4B) on S406. Depletion of PIM1 decreased cell proliferation, migration, invasion and colony formation in vitro, as well as reduced tumor growth in vivo. And these effects were partially abrogated by restoring of c-MET expression. Our study implicates a promising therapeutic approach in lung adenocarcinoma patients with PIM1 and c-MET over expression.
引用
收藏
页码:116 / 126
页数:11
相关论文
共 51 条
  • [1] Alam H., 2018, CANC RES
  • [2] Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET plus NSCLC
    Bauer, Todd M.
    Schuler, Martin
    Berardi, Rossana
    Lim, Wan-Teck
    Van Geel, Robin
    De Jonge, Maja
    Azaro, Analia
    Gottfried, Maya
    Han, Ji-Youn
    Lee, Dae Ho
    Wollner, Mira
    Hong, David
    Voge, Arndt
    Delmonte, Angelo
    Krohn, Alexander
    Zhang, Yong
    Squires, Matthew
    Giovannini, Monica
    Akimov, Mikhail
    Kim, Dong-Wan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S257 - S258
  • [3] Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia
    Bellon, Marcia
    Lu, Ling
    Nicot, Christophe
    [J]. BLOOD, 2016, 127 (20) : 2439 - 2450
  • [4] Met, metastasis, motility and more
    Birchmeier, C
    Birchmeier, W
    Gherardi, E
    Vande Woude, GF
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) : 915 - 925
  • [5] Induction of epithelial tubules by growth factor HGF depends on the STAT pathway
    Boccaccio, C
    Andò, M
    Tamagnone, L
    Bardelli, A
    Michieli, P
    Battistini, C
    Comoglio, PM
    [J]. NATURE, 1998, 391 (6664) : 285 - 288
  • [6] Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
    Cabanillas, Maria E.
    de Souza, Jonas A.
    Geyer, Susan
    Wirth, Lori J.
    Menefee, Michael E.
    Liu, Stephen V.
    Shah, Komal
    Wright, John
    Shah, Manisha H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3315 - +
  • [7] A genetic variant that disrupts MET transcription is associated with autism
    Campbell, Daniel B.
    Sutcliffe, James S.
    Ebert, Philip J.
    Militerni, Roberto
    Bravaccio, Carmela
    Trillo, Simona
    Elia, Maurizio
    Schneider, Cindy
    Melmed, Raun
    Sacco, Roberto
    Persico, Antonio M.
    Levitt, Pat
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (45) : 16834 - 16839
  • [8] Targeting the HGF/Met signaling pathway in cancer therapy
    Cecchi, Fabiola
    Rabe, Danie C.
    Bottaro, Donald P.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (06) : 553 - 572
  • [9] The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling
    Cen, Bo
    Xiong, Ying
    Song, Jin H.
    Mahajan, Sandeep
    DuPont, Rachel
    McEachern, Kristen
    DeAngelo, Daniel J.
    Cortes, Jorge E.
    Minden, Mark D.
    Ebens, Allen
    Mims, Alice
    LaRue, Amanda C.
    Kraft, Andrew S.
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2014, 34 (13) : 2517 - 2532
  • [10] Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia
    Chen, Lisa S.
    Redkar, Sanjeev
    Taverna, Pietro
    Cortes, Jorge E.
    Gandhi, Varsha
    [J]. BLOOD, 2011, 118 (03) : 693 - 702